Drug class
Immunosuppressant antimetabolite; mycophenolic acid active moiety
Mechanism of action
Inhibits inosine monophosphate dehydrogenase (IMPDH), preferentially suppressing de-novo guanosine nucleotide synthesis in activated T and B lymphocytes and reducing lymphocyte proliferation. Specific prodrug salts/forms such as mycophenolate mofetil and mycophenolate sodium are separate dosage forms that deliver mycophenolic acid.
General use cases
- Used in combination immunosuppressive regimens to prevent allograft rejection after kidney, heart or liver transplantation, depending on the particular mycophenolic acid formulation and jurisdiction
- Off-label use in selected autoimmune disorders is not a universal product-authorised indication
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
